A national survey on current use of mycophenolate mofetil for childhood-onset systemic lupus erythematosus in Japan

Ryoki Hara, Hirotaka Miyazawa, Kenichi Nishimura, Takahiro Momoi, Tomo Nozawa, Masako Kikuchi, Nodoka Sakurai, Toshitaka Kizawa, Sanae Shimamura, Shinsuke Yasuda, Keiju Hiromura, Kenei Sada, Yasushi Kawaguchi, Naoto Tamura, Syuji Takei, Yoshinari Takasaki, Tatsuya Atsumi, Masaaki Mori

Research output: Contribution to journalArticle

Abstract

Purpose. To conduct a national survey of systemic lupus erythematosus (SLE) patients treated with mycophenolate mofetil (MMF). Based on current information on the use of MMF, we aimed to evaluate its efficacy and safety for childhood-onset (c-) SLE. Target. We evaluated 115 patients by questionnaire on MMF use for c-SLE in medical facilities specializing in pediatric rheumatic and renal diseases. Results. Average age at SLE onset was 10.6 (range, 2-15) years; average age at the time of starting MMF was 12.3 (range, 2-15) years. Average dose per body surface area was 1,059.3 mg/m2/day. Corticosteroid dosing was 20.9 mg/day before treatment but 7.7 mg/day after treatment. Laboratory values before and after MMF treatment were as follows: C3 increased from 67.0 to 84.9 mg/dl (p <0.001), C4 increased from 10.2 to 15.1 mg/dl (p <0.001), and anti-DNA antibody decreased from 154.2 to 18.4 IU/ml (p <0.001). 24 adverse events in 21 cases were reported, but MMF was not discontinued in any. Conclusions. The amount of MMF for c-SLE in Japan is similar to the standard dose in other countries. Reduction of corticosteroid dose and improvement of laboratory values represent efficacy of MMF. The side effects recorded here indicated tolerability of the drug.

Original languageEnglish
Pages (from-to)858-864
Number of pages7
JournalModern Rheumatology
Volume25
Issue number6
DOIs
Publication statusPublished - Sep 8 2015

Fingerprint

Mycophenolic Acid
Systemic Lupus Erythematosus
Japan
Adrenal Cortex Hormones
Surveys and Questionnaires
Body Surface Area
Antinuclear Antibodies
Rheumatic Diseases
Therapeutics
Pediatrics
Kidney
Safety

Keywords

  • Childhood-onset systemic lupus erythematosus
  • Effectiveness
  • Lupus nephritis
  • Mycophenolate mofetil
  • Tolerability

ASJC Scopus subject areas

  • Rheumatology

Cite this

A national survey on current use of mycophenolate mofetil for childhood-onset systemic lupus erythematosus in Japan. / Hara, Ryoki; Miyazawa, Hirotaka; Nishimura, Kenichi; Momoi, Takahiro; Nozawa, Tomo; Kikuchi, Masako; Sakurai, Nodoka; Kizawa, Toshitaka; Shimamura, Sanae; Yasuda, Shinsuke; Hiromura, Keiju; Sada, Kenei; Kawaguchi, Yasushi; Tamura, Naoto; Takei, Syuji; Takasaki, Yoshinari; Atsumi, Tatsuya; Mori, Masaaki.

In: Modern Rheumatology, Vol. 25, No. 6, 08.09.2015, p. 858-864.

Research output: Contribution to journalArticle

Hara, R, Miyazawa, H, Nishimura, K, Momoi, T, Nozawa, T, Kikuchi, M, Sakurai, N, Kizawa, T, Shimamura, S, Yasuda, S, Hiromura, K, Sada, K, Kawaguchi, Y, Tamura, N, Takei, S, Takasaki, Y, Atsumi, T & Mori, M 2015, 'A national survey on current use of mycophenolate mofetil for childhood-onset systemic lupus erythematosus in Japan', Modern Rheumatology, vol. 25, no. 6, pp. 858-864. https://doi.org/10.3109/14397595.2015.1077555
Hara, Ryoki ; Miyazawa, Hirotaka ; Nishimura, Kenichi ; Momoi, Takahiro ; Nozawa, Tomo ; Kikuchi, Masako ; Sakurai, Nodoka ; Kizawa, Toshitaka ; Shimamura, Sanae ; Yasuda, Shinsuke ; Hiromura, Keiju ; Sada, Kenei ; Kawaguchi, Yasushi ; Tamura, Naoto ; Takei, Syuji ; Takasaki, Yoshinari ; Atsumi, Tatsuya ; Mori, Masaaki. / A national survey on current use of mycophenolate mofetil for childhood-onset systemic lupus erythematosus in Japan. In: Modern Rheumatology. 2015 ; Vol. 25, No. 6. pp. 858-864.
@article{4f05aa2528b7418fbe54f4e0973c2e6f,
title = "A national survey on current use of mycophenolate mofetil for childhood-onset systemic lupus erythematosus in Japan",
abstract = "Purpose. To conduct a national survey of systemic lupus erythematosus (SLE) patients treated with mycophenolate mofetil (MMF). Based on current information on the use of MMF, we aimed to evaluate its efficacy and safety for childhood-onset (c-) SLE. Target. We evaluated 115 patients by questionnaire on MMF use for c-SLE in medical facilities specializing in pediatric rheumatic and renal diseases. Results. Average age at SLE onset was 10.6 (range, 2-15) years; average age at the time of starting MMF was 12.3 (range, 2-15) years. Average dose per body surface area was 1,059.3 mg/m2/day. Corticosteroid dosing was 20.9 mg/day before treatment but 7.7 mg/day after treatment. Laboratory values before and after MMF treatment were as follows: C3 increased from 67.0 to 84.9 mg/dl (p <0.001), C4 increased from 10.2 to 15.1 mg/dl (p <0.001), and anti-DNA antibody decreased from 154.2 to 18.4 IU/ml (p <0.001). 24 adverse events in 21 cases were reported, but MMF was not discontinued in any. Conclusions. The amount of MMF for c-SLE in Japan is similar to the standard dose in other countries. Reduction of corticosteroid dose and improvement of laboratory values represent efficacy of MMF. The side effects recorded here indicated tolerability of the drug.",
keywords = "Childhood-onset systemic lupus erythematosus, Effectiveness, Lupus nephritis, Mycophenolate mofetil, Tolerability",
author = "Ryoki Hara and Hirotaka Miyazawa and Kenichi Nishimura and Takahiro Momoi and Tomo Nozawa and Masako Kikuchi and Nodoka Sakurai and Toshitaka Kizawa and Sanae Shimamura and Shinsuke Yasuda and Keiju Hiromura and Kenei Sada and Yasushi Kawaguchi and Naoto Tamura and Syuji Takei and Yoshinari Takasaki and Tatsuya Atsumi and Masaaki Mori",
year = "2015",
month = "9",
day = "8",
doi = "10.3109/14397595.2015.1077555",
language = "English",
volume = "25",
pages = "858--864",
journal = "Modern Rheumatology",
issn = "1439-7595",
publisher = "Springer Japan",
number = "6",

}

TY - JOUR

T1 - A national survey on current use of mycophenolate mofetil for childhood-onset systemic lupus erythematosus in Japan

AU - Hara, Ryoki

AU - Miyazawa, Hirotaka

AU - Nishimura, Kenichi

AU - Momoi, Takahiro

AU - Nozawa, Tomo

AU - Kikuchi, Masako

AU - Sakurai, Nodoka

AU - Kizawa, Toshitaka

AU - Shimamura, Sanae

AU - Yasuda, Shinsuke

AU - Hiromura, Keiju

AU - Sada, Kenei

AU - Kawaguchi, Yasushi

AU - Tamura, Naoto

AU - Takei, Syuji

AU - Takasaki, Yoshinari

AU - Atsumi, Tatsuya

AU - Mori, Masaaki

PY - 2015/9/8

Y1 - 2015/9/8

N2 - Purpose. To conduct a national survey of systemic lupus erythematosus (SLE) patients treated with mycophenolate mofetil (MMF). Based on current information on the use of MMF, we aimed to evaluate its efficacy and safety for childhood-onset (c-) SLE. Target. We evaluated 115 patients by questionnaire on MMF use for c-SLE in medical facilities specializing in pediatric rheumatic and renal diseases. Results. Average age at SLE onset was 10.6 (range, 2-15) years; average age at the time of starting MMF was 12.3 (range, 2-15) years. Average dose per body surface area was 1,059.3 mg/m2/day. Corticosteroid dosing was 20.9 mg/day before treatment but 7.7 mg/day after treatment. Laboratory values before and after MMF treatment were as follows: C3 increased from 67.0 to 84.9 mg/dl (p <0.001), C4 increased from 10.2 to 15.1 mg/dl (p <0.001), and anti-DNA antibody decreased from 154.2 to 18.4 IU/ml (p <0.001). 24 adverse events in 21 cases were reported, but MMF was not discontinued in any. Conclusions. The amount of MMF for c-SLE in Japan is similar to the standard dose in other countries. Reduction of corticosteroid dose and improvement of laboratory values represent efficacy of MMF. The side effects recorded here indicated tolerability of the drug.

AB - Purpose. To conduct a national survey of systemic lupus erythematosus (SLE) patients treated with mycophenolate mofetil (MMF). Based on current information on the use of MMF, we aimed to evaluate its efficacy and safety for childhood-onset (c-) SLE. Target. We evaluated 115 patients by questionnaire on MMF use for c-SLE in medical facilities specializing in pediatric rheumatic and renal diseases. Results. Average age at SLE onset was 10.6 (range, 2-15) years; average age at the time of starting MMF was 12.3 (range, 2-15) years. Average dose per body surface area was 1,059.3 mg/m2/day. Corticosteroid dosing was 20.9 mg/day before treatment but 7.7 mg/day after treatment. Laboratory values before and after MMF treatment were as follows: C3 increased from 67.0 to 84.9 mg/dl (p <0.001), C4 increased from 10.2 to 15.1 mg/dl (p <0.001), and anti-DNA antibody decreased from 154.2 to 18.4 IU/ml (p <0.001). 24 adverse events in 21 cases were reported, but MMF was not discontinued in any. Conclusions. The amount of MMF for c-SLE in Japan is similar to the standard dose in other countries. Reduction of corticosteroid dose and improvement of laboratory values represent efficacy of MMF. The side effects recorded here indicated tolerability of the drug.

KW - Childhood-onset systemic lupus erythematosus

KW - Effectiveness

KW - Lupus nephritis

KW - Mycophenolate mofetil

KW - Tolerability

UR - http://www.scopus.com/inward/record.url?scp=84947046175&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947046175&partnerID=8YFLogxK

U2 - 10.3109/14397595.2015.1077555

DO - 10.3109/14397595.2015.1077555

M3 - Article

C2 - 26215483

AN - SCOPUS:84947046175

VL - 25

SP - 858

EP - 864

JO - Modern Rheumatology

JF - Modern Rheumatology

SN - 1439-7595

IS - 6

ER -